Letter from the Chairman
- Home
- Sustainability
- Letter from the Chairman
Senhwa Biosciences is a Taiwan-based company with a global outlook, focusing on the development of First-in-Class new drugs with novel mechanisms of action. The company’s mission, "Bringing Hope to Life," aims to benefit more patients and bring a better life to humanity.
2024 marks a significant leap forward in Senhwa Biosciences research and development achievements. Two of the company’s developing drugs, Pidnarulex (CX-5461) and Silmitasertib (CX-4945), have been selected by the U.S. National Cancer Institute to enter a five-year cancer research funding program, known as the NCI Experimental Therapeutics(NExT) Program and initiate human clinical trials. In addition, Silmitasertib has been chosen by the well-known Beat Childhood Cancer Research Consortium in the U.S. for clinical use in treating multiple pediatric cancers. The drug has also received orphan drug status and rare pediatric disease designations, which could offer a seven-year market exclusivity in the U.S. and the possibility of expedited review after approval.
At the same time, 2024 is also the year that Senhwa Biosciences implants ESG DNA into its corporate sustainability strategy. We have established a Sustainability Development Committee under the Board of Directors to declare our commitment to corporate sustainability, set strategic goals, and make promises. A Sustainability and Stakeholder Office and four functional teams have also been set up to oversee the implementation of sustainability work, including four major areas: Environment (E), Social (S), Governance (G), and Product Ethics and Safety (P), as well as setting sustainability indicators and performance targets.
From an environmental perspective, in response to global warming issues and to mitigate the risks associated with climate change, we will implement the “ISO 14064-1:2018 Greenhouse Gas Inventory” project in 2025. This will involve measuring greenhouse gas emissions to establish our company's carbon reduction targets. From a social perspective, we emphasize building a learning-oriented company, focusing on talent development, and striving to create a friendly, diverse, and inclusive workplace. In terms of corporate governance and operational strategy, We have successively recruited former senior executives from major international pharmaceutical companies to hold key positions. Their international perspectives, networks, and extensive experience in biotech and pharmaceuticals will lead the company’s strategic development and connect us to global networks.
On governance, the board emphasizes diversity and independence, increasing the number of female board members to three (43%). In the 112th annual governance evaluation, we were ranked as the top team in the Over-the-Counter company category, reflecting the board and management team's commitment to corporate governance culture.
Looking forward, our vision is to become a world-class company specializing in market-first new drugs and rare disease treatments. Through licensing and international collaborations, we aim to shorten the development timeline for drug market entry, enabling more patients in various disease areas to benefit. Our goal is to let more people experience the essence of life and, at the same time, establish ourselves as a globally influential, sustainable new drug development company.
Chairman of the Board Benny T. Hu